NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Want to cut your energy bills? Here’s how five experts are doing it 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
SAN DIEGO, March 02, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended December 31, 2016, before the opening of trading on Thursday, March 9, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, March 9. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (913) 312-0639 (preferred), or (888) 778-8903 (toll-free), and reference confirmation code 9560352. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 9560352. The call also will be available live and archived through the events page at www.vical.com.
Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to [email protected] or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by email at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Andrew Hopkins (858) 646-1127 Website: www.vical.com
